— Know what they know.
Not Investment Advice

INZY NASDAQ

Inozyme Pharma, Inc.
1W: +0.2% 1M: +0.5% 3M: +359.8% 1Y: -10.3% 3Y: -22.5%
$4.00
Last traded 2025-07-02 — delisted
NASDAQ · Healthcare · Biotechnology · $258.2M mcap · 43M float · 5.10% daily turnover · Short 51% of daily vol

Balance Sheet Trends

Total Assets
$123M -38.7% ▼
5Y CAGR: +20.8%
Total Liabilities
$65M +8.3% ▲
5Y CAGR: -4.2%
Shareholders Equity
$58M -58.8% ▼
Cash & Investments
$113M -40.0% ▼
5Y CAGR: +19.1%
Total Debt
$47M +0.6% ▲
Net Debt
$26M +114.9% ▲

Assets vs Liabilities & Equity

Year-over-Year Growth

View Full Balance Sheet
Line ItemFY2020FY2021FY2022FY2023FY2024
— Assets —
Cash$160M$23M$33M$35M$21M
Short-Term Investments$0$88M$95M$154M$92M
Cash & ST Investments$160M$112M$128M$189M$113M
Net Receivables$155K$62K$115K$385K$467K
Inventory-$12M-$62K-$115K$0$0
Other Current Assets$0$0$0$0$311K
Total Current Assets$151M$115M$131M$196M$121M
Property, Plant & Equip.$3M$4M$4M$3M$1M
Goodwill & Intangibles$0$0$0$0$0
Long-Term Investments$12M$354K$354K$0$0
Other Non-Current Assets$4M$3M$4M$2M$1M
Total Non-Current Assets$18M$8M$8M$5M$3M
Total Assets$169M$124M$139M$201M$123M
— Liabilities —
Accounts Payable$3M$2M$3M$1M$3M
Short-Term Debt$0$731K$816K$0$15M
Deferred Revenue$279K$0$4M$0$0
Other Current Liabilities$279K$5M$8M$9M$12M
Total Current Liabilities$10M$12M$15M$15M$34M
Long-Term Debt$0$0$4M$45M$31M
Other Non-Current Liab.$0$0$124K$0$0
Total Non-Current Liabilities$1M$3M$6M$46M$31M
Total Liabilities$11M$14M$21M$60M$65M
— Equity —
Common Stock$2K$2K$4K$6K$6K
Retained Earnings-$91M-$148M-$215M-$286M-$388M
Accumulated OCI$2K$18K-$205K$41K$69K
Total Stockholders Equity$158M$109M$119M$140M$58M
Total Liabilities & Equity$169M$124M$139M$201M$123M
— Key Metrics —
Total Debt$1M$3M$7M$47M$47M
Net Debt-$159M-$20M-$26M$12M$26M
Total Investments$12M$88M$95M$154M$92M

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms